The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 April 2026•

1 min read

BioNxt Completes GMP Manufacturing of Sublingual Cladribine for MS Treatment

Key Facts

1BioNxt completed GMP manufacturing of its sublingual Cladribine oral thin film in Munich, Germany.

2The production campaign marks a significant operational milestone for the lead development program BNT23001 targeting MS.

BioNxt Solutions Inc. has successfully completed the GMP manufacturing of its clinical-grade sublingual Cladribine oral thin film in Munich, Germany. This production milestone is a critical advancement for the company's lead development program, BNT23001, which targets Multiple Sclerosis (MS). The completion of this manufacturing campaign prepares the company for upcoming clinical trials and the evaluation of its proprietary drug delivery system. By achieving GMP standards, BioNxt has significantly de-risked its operational path toward potential commercialization. This development is expected to bolster investor confidence in the company's biotech pipeline and its focus on autoimmune neurodegenerative diseases. Analysts view this as a pivotal step in the company's transition from development to clinical evaluation phases.